Pacific Biosciences of California, Inc. (PACB)

Market Cap	502.68M +17.7%
Revenue (ttm)	160.01M +3.9%
Net Income	-546.38M
EPS	-1.82
Shares Out	301.91M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,602,128
Open	1.680
Previous Close	1.660
Day's Range	1.640 - 1.710
52-Week Range	0.851 - 2.730
Beta	2.28
Analysts	Buy
Price Target	2.08 (+24.93%)
Earnings Date	Feb 12, 2026

About PACB

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified ...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Oct 27, 2010
• Employees: 575
• Stock Exchange: NASDAQ
• Ticker Symbol: PACB
• Website: https://www.pacb.com

Financial Performance

In 2025, PACB's revenue was $160.01 million, an increase of 3.89% compared to the previous year's $154.01 million. Losses were -$546.38 million, 76.3% more than in 2024.

Analyst Summary

According to 6 analysts, the average rating for PACB stock is "Buy." The 12-month stock price target is $2.08, which is an increase of 24.93% from the latest price.

Price Target

$2.08

(24.93% upside)

Analyst Consensus: Buy